Overview
- The agreement includes $250 million in cash and $370 million in Mirum stock upfront, with up to $200 million in sales-based milestones.
- Mirum gains worldwide rights to brelovitug, a monoclonal antibody for chronic hepatitis D now in a late-stage study.
- In a mid-stage trial, all treated patients showed reductions in hepatitis D virus levels and up to 82% had normalized liver enzymes, according to the companies.
- Phase 3 results are expected in the second half of 2026, with Mirum planning a U.S. filing and a potential 2027 launch if outcomes are positive.
- Closing is targeted for the first quarter of 2026, and Mirum will evaluate strategic options for Bluejay’s other pipeline programs.